Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study

Journal of Research in Medical Sciences

Volumn 16, Issue 1, 2011, Pages 1-5

  Etemadifar, Masoud ^a   Kazemi, Mojtaba ^a   Chitsaz, Ahmad ^a   Hekmatnia, Ali ^a   Tayari, Nazila ^a   Ghazavi, Amirhossein ^a   Maghzi, Amir Hadi ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunosuppressive; Interferon Beta 1a; Mycophenolate Mofetil; Relapsing Remitting Multiple Sclerosis

Indexed keywords

BETA1A INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

EID: 79551714521     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52.
2. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010;221(1-2):7-14.
3. Kieseier BC, Wiendl H, Leussink VI, Stüve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 2008;255(Suppl 6):15-21.
4. Gauthier SA, Buckle GJ, Weiner HL. Immunosuppressive therapy for multiple sclerosis. Neurol Clin 2005;23(1):247-72, viii-ix.
5. Chofflon M. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 2000;7(4):369-80.
6. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002.
7. Gold R. Combination therapies in multiple sclerosis. J Neurol 2008;255(Suppl 1):51-60.
8. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 2004;63(12 Suppl 6):S41-6.
9. Vermersch P, Waucquier N, Michelin E, Bourteel H, Stojkovic T, Ferriby D, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007;14(1):85-9.
10. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248(8):713-4.
11. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27(2):80-3.
12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58(6):840-6.
13. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004;4:26.
14. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6(3):190-5.
15. Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing remitting multiple sclerosis. Ther Adv Neurol Disord 2010;3(1):15-28.